Flumazenil (Anexate - Roche) is the first benzodiazepine receptor antagonist to be marketed. The i.v. injection is licenced for termination of general anaesthesia induced or maintained with benzodiazepines, for the reversal of benzodiazepine sedation in short diagnostic or therapeutic procedures, and in intensive care. We discuss the value of flumazenil in these situations.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.